ClinicalTrials.gov
public full text
Public Domain
The Role of Endothelin-1 in Sickle Cell Disease
The primary goal of the study is to determine the safety and tolerability of ambrisentan. It is also expected that ambrisentan will improve blood flow in the lungs, decrease inflammation, and reduce pain in sickle cell patients. An additional goal is to evaluate the use of select biomarkers in evaluating sickle nephropathy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy#829195
- Contrast Nephropathy Associated FFA#994172
- Arterial Function Parameters and Transcranial Doppler Velocity in Paediatric Patients With Sickle Cell Disease#1009915
- Flow-mediated Arterial Dilatation, Hypertension, Endothelin-1 and sICAM-1 in Obese Adolescents#861730
- Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease#123589
Record · ID 838726
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive